ORIGINALARTICLE : Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure

Background/Aims: We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous an-tiviral therapies. Methods: Seventeen patients who failed to achieve virological responses during sequential antiviral treatmen...

Full description

Saved in:
Bibliographic Details
Published in:Gut and liver 2014-01, Vol.8 (1), p.64
Main Authors: Jeong Han Kim, Yun Soo Kim, So Young Kwon, Chang Hong Lee, Kwan Soo Byun, Ju Hyun Kim, Jong Eun Yeon, Won Hyeok Choe, Eileen L Yoon, Cho I Lee
Format: Article
Language:Korean
Subjects:
Antiviral agents
Hepatitis B
Resistance
Tenofovir
Treatment outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aims: We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous an-tiviral therapies. Methods: Seventeen patients who failed to achieve virological responses during sequential antiviral treatments were included. The patients were treated with TDF monotherapy (four patients) or a combination of TDF and lamivudine (13 patients) for a median of 42 months. Hepatitis B virus (HBV) DNA and hepatitis B e antigen (HBeAg) were measured, and renal function was also monitored. Re-sults: Prior to TDF therapy, 180 M, 204 I/V/S, 181 T/V, 236 T, and 184 L mutations were detected. After TDF therapy, the median HBV DNA level decreased from 4.6 log10 IU/mL to 2.0 log10 IU/mL and to 1.6 log10 IU/mL at 12 and 24 months, respectively. HBV DNA became undetectable (≤20 IU/mL) in 14.3%, 41.7%, and 100% of patients after 12, 24, and 48 months of treatment, respectively. HBeAg loss was observed in two patients. Viral breakthrough occurred in five patients who had skipped their medication. No significant changes in renal function were observed. Conclusions: TDF-based rescue treatment is effective in reducing HBV DNA levels and is safe for patients with CHB who failed prior antiviral treat-ments. Patients’ adherence to medication is related to viral rebound.
ISSN:1976-2283